☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Sobi
Sobi’s Altuvoct Receives the EC’s Marketing Authorization to Treat Haemophilia A
June 19, 2024
Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A
May 19, 2023
Sobi to Acquire CTI BioPharma for ~$1.7B
May 11, 2023
PharmaShots' Key Highlights of First Quarter 2023
April 3, 2023
Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-...
December 21, 2022
Sobi and Sanofi Report Results of Efanesoctocog Alfa (BIVV001) in P-III (XTEND-1) study for the Treatment of Haemophilia A
March 9, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.